FGFR4 and hepatocellular carcinoma: In conclusion, our study shows that (i) the advantage of lenvatinib in overcoming sorafenib-resistance may be through the FGFR4-ERK signaling pathway; (ii) HBV DNA and poor autophagic responsiveness may be the reasons for partial cross-resistance; (iii) miRNA alterations may contribute to inhibiting sorafenib-resistant HCC cell growth and angiogenesis.